- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04946591
Feasibility and Impact of ICG and 4K Overlay in Laparoscopic Hepatic Surgery on Real-time Tumor Detection (LiverLight)
October 4, 2023 updated by: Dr.med Dr. habil Gregor A. Stavrou, Klinikum Saarbrücken, Klinik für Allgemein-, Viszeral- und Thoraxchirurgie, Chirurgische Onkologie
Feasibility and Impact of ICG and 4K Overlay in Laparoscopic Hepatic Surgery on Real-time Tumor Detection: A Single-centre Prospective Study
Achievement of tumor-free resection margin with the largest possible remnant liver parenchyma is the major challenge in hepatic surgery.
Therefore, perioperative tumor detection, anatomical mapping of liver segments and also nearby structures are vital to improve the short- and long-term surgical outcomes.
Over last decades, several real-time methods have been introduced for this purpose.
These methods are mostly based on the utilizing of traceable dyes, which are excreted into the biliary tract.
With the advances in minimal invasive surgery and video technology, indocyanine green became the most used dye in this manner.
It has been demonstrated that using indocyanine green, small liver tumors can be detected, which cannot be identified using conventional intraoperative methods.
Based on the literature, the reported sensitivity of tumor detection using indocyanine green is ranging between 98%-100%, while conventional methods could not reach 90% sensitivity.
Posthepatectomy bile leakage, as well as in- or outflow distributions due to the potential vascular reconstructions, are some of the most common complications that can occur especially after complex liver surgeries.
Beside the abovementioned advantages of indocyanine green, several researchers have also shown the feasibility of indocyanine green to identify the intraoperative bile leaks and any in- or outflow distributions.
Nevertheless, laparoscopic assisted liver surgery is technically challenging, mostly because of the restricted degrees of instrument movements, camera instability, and loss of depth perception.
In particular, the loss of depth perception and inaccurate object localization can lead to intraoperative complications and a long learning curve.
Advances in video technology, namely 4K ultra-high-definition imaging have been developed to reduce perioperative complications and to shorten the learning curve during laparoscopic liver surgery.
This is the first prospective study evaluating the impact of indocyanine green imaging during 4K laparoscopic liver surgery on real-time tumor detection and surgical outcomes.
Study Overview
Status
Recruiting
Conditions
Study Type
Observational
Enrollment (Estimated)
50
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Gregor A. Stavrou, MD
- Phone Number: 0049681963 2441
- Email: gstavrou@klinikum-saarbruecken.de
Study Locations
-
-
Saarland
-
Saarbrücken, Saarland, Germany, 66119
- Recruiting
- Klinikum Saarbrücken
-
Contact:
- Gregor A. Stavrou, Dr. Dr. habil
- Phone Number: 00496819632441
- Email: gstavrou@klinikum-saarbruecken.de
-
Contact:
- Omid Ghamar Nejad, MD
- Phone Number: 00496819632441
- Email: oghamar@klinikum-saarbruecken.de
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
N/A
Sampling Method
Non-Probability Sample
Study Population
Adult patients with any type of liver tumor undergoing 4K laparoscopic hepatectomy using indocyanine green
Description
Inclusion Criteria:
- Patient consent
- Aged above 18 years
- Undergoing any type of liver resections
Exclusion Criteria:
- Unresectable liver tumors
- Known indocyanine green allergy
- Iodine allergy
- Advanced cirrhosis (Child C)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Tumor localization
Time Frame: One day
|
One day
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Remnant liver venous drainage
Time Frame: One day
|
One day
|
|
Detection of resection plane
Time Frame: One day
|
One day
|
|
Rate of intraoperative bile leak
Time Frame: One day
|
Using indocyanine green and fluorescence camera
|
One day
|
Rate of postoperative bile leak
Time Frame: Three months
|
Based on the ISGLS criteria
|
Three months
|
Resection margin
Time Frame: One day
|
Using fluorescence camera
|
One day
|
Rate of morbidity
Time Frame: Three months
|
Based on the Clavien-Dindo classification
|
Three months
|
Duration of hospital stay
Time Frame: Three months
|
Three months
|
|
Rate of mortality
Time Frame: Three months
|
All cause death events
|
Three months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 1, 2021
Primary Completion (Estimated)
April 1, 2024
Study Completion (Estimated)
June 1, 2024
Study Registration Dates
First Submitted
June 19, 2021
First Submitted That Met QC Criteria
June 23, 2021
First Posted (Actual)
July 1, 2021
Study Record Updates
Last Update Posted (Actual)
October 5, 2023
Last Update Submitted That Met QC Criteria
October 4, 2023
Last Verified
October 1, 2023
More Information
Terms related to this study
Other Study ID Numbers
- 26/21
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Laparoscopic Hepatectomy
-
Sichuan UniversityNot yet recruitingLaparoscopic HepatectomyChina
-
IGI Technologies, Inc.National Cancer Institute (NCI); National Institutes of Health (NIH); University...UnknownLaparoscopic Hepatectomy | Laparoscopic Liver Thermal AblationUnited States
-
Sun Yat-sen UniversityUnknownLaparoscopic HepatectomyChina
-
ZhangyiNot yet recruitingNerve Block | Laparoscopic HepatectomyChina
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRecruitingHepatocellular Carcinoma | Laparoscopic HepatectomyChina
-
Hospital Italiano de Buenos AiresCompleted
-
Rennes University HospitalMinistry of Health, FranceCompleted
-
University Hospital HeidelbergUnknown
-
Sir Run Run Shaw HospitalCompleted
-
Seoul National University HospitalCompleted